bs-60138C [Life Science]
SGC-CBP30 --- p300/CBP Bromodomain Inhibitor
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Formulation Powder

Storage: Store in dry, dark place at -20C for 1 year.

Product Information:

Molecular Weight: 509.04

Formula: C28 H33 Cl N4 O3

CAS Number: 1613695-14-9

InChi Key: GEPYBHCJBORHCE-SFHVURJKSA-N

InChi: InChI=1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1

Smiles: COC1C=CC(CCC2=NC3C=C(C=CC=3N2C[C@H](C)N2CCOCC2)C2=C(C)ON=C2C)=CC=1Cl

Purity: 98.0

Solubility: DMSO up to 100 mM

Appearance: Solid Power.

Shelf Life: 1.0 years

Description:

SGC-CBP30 is a highly potent and selective p300/CBP bromodomain inhibitor (IC50 ~0.021-0.069 μM for CBP and ~0.038 μM for p300). It has 40-fold selectivity for CBP over BRD4. It accelerated FRAP recovery at 1 μM. p300 and CBP are transcriptional co-activators that modulate DNA replication, DNA repair, cell growth, transformation, and development. Both p300 and CBP contain bromodomains, which mediate their binding to acetylated lysine residues on histones and other proteins. Chromosomal translocations of p300 or CBP with MOZ, MLL have been observed in acute myeloid leukemia. CBP has also been associated with Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease with progressive degeneration of motor neurons in the brain and spinal cord, Alzheimer's disease and polyglutamine diseases such as Spinal and Bulbar Muscular Atrophy and Huntington’s disease.

Size: 10mg solid, 2 mg solid,10 mM in DMSO (0.393 10mg solid, 2 mg solid,10 mM in DMSO (0.393 mL)

Applications: Life Science()

For research use only. Not intended for diagnostic or therapeutic use.